Vitrolife (Q3 review): Technologies leads the way - Redeye

Vitrolife’s Q3 sales came in 4% above consensus at SEK884m, driven by 21% organic growth in Technologies, while the adjusted EBITDA margin of 30.5% was slightly below expectations. The market read the accelerated organic growth positively, sending the share up 5%. The stock screens as “Attractively Priced” at a c21% discount to Redeye’s raised fair value of SEK130.

Länk till analysen i sin helhet: https://www.redeye.se/research/1188297/vitrolife-q3-review-technologies-leads-the-way?utm_source=finwire&utm_medium=RSS